New Report Examines Drug Shortages

New Report Examines Drug Shortages News & Analysis News From the Food and Drug Administration Clarithromycin-Resistant H pylori sis, the first triple-combination therapy that tion, sweat chloride concentration, and re- Faces New Foe treats the underlying cause of most pa- spiratory quality of life compared with the The FDA has approved a combination drug tients’ disease has received FDA approval. tezacaftor-ivacaftor group. for Helicobacter pylori infection that’s Marketed as Trikafta, the drug com- Serious adverse events associated with designed to address high rates of resistance bines elexacaftor, tezacaftor, and ivacaftor. Trikafta in both trials were rash and influ- to standard clarithromycin-based treat- The trio improves the function of the abnor- enza. Common adverse events included ment, according to manufacturer RedHill mal cystic fibrosis transmembrane conduc- headache, upper respiratory tract infec- Biopharma Ltd of Tel Aviv, Israel. In 2017, tance regulator (CFTR) protein resulting tion, abdominal pain, diarrhea, and in- the World Health Organization designated from a genetic mutation that’s responsible creased liver enzymes. the need for new antibiotics against H pylori for about 90% of cystic fibrosis cases. The as a high priority. drug is indicated for patients aged 12 years A combination of the antibiotics rifabu- or older who have at least 1 copy of the An FDA report has offered a snapshot of tin and amoxicillin along with the proton F508del CFTR mutation. drugs subject to shortages in recent years: pump inhibitor omeprazole magnesium, they’re often sterile injectables that have a the drug is marketed as Talicia. In a phase 3 generic version and have been on the mar- trial, 119 patients with H pylori infection ket perhaps for decades. But once they oc- were randomized to receive Talicia or pla- cur, why do the shortages persist? In a word, cebo for 14 days. Infection was eradicated economics. in 89.4% of patients in the treatment group The report comes after members of Con- compared with 2.7% in the placebo group. gress in 2018 urged the FDA to convene a In a confirmatory phase 3 trial, a RedHill task force to examine the issue and offer po- statement noted that H pylori was eradi- tential solutions. In response, officials from cated in 84% of patients in the Talicia the FDA and several other federal agencies group compared with 58% in a group that analyzed 163 drugs that were in short sup- received amoxicillin and omeprazole. ply from 2013 to 2017 and compared them Treatment with 2 CFTR modulators is ef- Adverse reactions included nausea, vomit- with more readily available drugs. ing, and nasal congestion. fectiveforpeoplewithcysticfibrosiswhoare “Shortage drugs were more likely to be “The clinical studies for Talicia demon- homozygous for that mutation. But those relatively low-price and financially unattract- strated high efficacy in eradication of who have a single F508del allele and an- ive drugs,” former Acting Commissioner Ned H pylori,” lead investigator David Y. Graham, other CFTR mutation—about 2000 are Sharpless, MD, and Janet Woodcock, MD, di- MD, of the Baylor College of Medicine in known—have no options to treat the under- rector of the FDA’s Center for Drug Evalua- Houston, said in a statement. The studies lying disease. These mutations are called tion and Research, wrote in a statement. “found zero resistance to rifabutin and minimal function because they result in Sharpless and Woodcock indicated that showed 17% resistance to clarithromycin, a either no CFTR protein production or non- prices rarely increased after shortages be- current standard-of-care macrolide antibi- response to CFTR modulators. gan and production subsequently didn’t rise otic, consistent with current data showing Efficacy was demonstrated in 2 phase 3 to meet demand. Many manufacturers, they trials involving patients with cystic fibrosis. that clarithromycin-containing therapies noted, discontinued drugs that no longer fail in approximately 25%-40% of cases,” In 1 trial, 403 patients with F508del mini- were profitable. mal function genotypes were randomized he added. “These results suggest a broken market- A2017 meta-analysis reported that to receive the triple-drug combination place,” they wrote. or placebo. After 24 weeks, the treated 4.4 billion people—more than half the Although solutions aren’t easy,Sharpless world’s population—had H pylori infection patients had improvements in lung func- and Woodcock recommended that data be tion, pulmonary exacerbations, sweat chlo- in 2015. Prevalence in the US general popu- gathered to quantify the effects of short- lation was 35.6%, but more than doubled ride concentration, and respiratory-related ages, a rating system be developed to quality of life. to 74.8% among Alaska Natives. Nigeria’s inform purchasers and consumers about 87.7% prevalence was the world’s highest; In the other trial, 107 patients who were manufacturers’ quality management, and 18.9% in Switzerland was the lowest. homozygous for the F508del mutation were contracting methods be updated to pro- randomized to receive Trikafta or 2 of its vide manufacturers, especially producers components, tezacaftor and ivacaftor. Af- of older generic drugs, with sustainable Patients With Cystic Fibrosis Have New Triple-Drug Combination ter 4 weeks, the investigators said that pa- returns. − Rebecca Voelker, MSJ Thirty years after investigators discovered tients treated with the 3-drug combination Note: Source references are available through the genetic defect that causes cystic fibro- embedded hyperlinks in the article text online. had “clinically robust” benefits in lung func- 2068 JAMA December 3, 2019 Volume 322, Number 21 (Reprinted) jama.com © 2019 American Medical Association. All rights reserved. James Cavallini/sciencesource.com http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

New Report Examines Drug Shortages

JAMA, Volume 322 (21) – Dec 3, 2019

Loading next page...
 
/lp/american-medical-association/new-report-examines-drug-shortages-YAVop9zZ1O
Publisher
American Medical Association
Copyright
Copyright 2019 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2019.19480
Publisher site
See Article on Publisher Site

Abstract

News & Analysis News From the Food and Drug Administration Clarithromycin-Resistant H pylori sis, the first triple-combination therapy that tion, sweat chloride concentration, and re- Faces New Foe treats the underlying cause of most pa- spiratory quality of life compared with the The FDA has approved a combination drug tients’ disease has received FDA approval. tezacaftor-ivacaftor group. for Helicobacter pylori infection that’s Marketed as Trikafta, the drug com- Serious adverse events associated with designed to address high rates of resistance bines elexacaftor, tezacaftor, and ivacaftor. Trikafta in both trials were rash and influ- to standard clarithromycin-based treat- The trio improves the function of the abnor- enza. Common adverse events included ment, according to manufacturer RedHill mal cystic fibrosis transmembrane conduc- headache, upper respiratory tract infec- Biopharma Ltd of Tel Aviv, Israel. In 2017, tance regulator (CFTR) protein resulting tion, abdominal pain, diarrhea, and in- the World Health Organization designated from a genetic mutation that’s responsible creased liver enzymes. the need for new antibiotics against H pylori for about 90% of cystic fibrosis cases. The as a high priority. drug is indicated for patients aged 12 years A combination of the antibiotics rifabu- or older who have at least 1 copy of the An FDA report has offered a snapshot of tin and amoxicillin along with the proton F508del CFTR mutation. drugs subject to shortages in recent years: pump inhibitor omeprazole magnesium, they’re often sterile injectables that have a the drug is marketed as Talicia. In a phase 3 generic version and have been on the mar- trial, 119 patients with H pylori infection ket perhaps for decades. But once they oc- were randomized to receive Talicia or pla- cur, why do the shortages persist? In a word, cebo for 14 days. Infection was eradicated economics. in 89.4% of patients in the treatment group The report comes after members of Con- compared with 2.7% in the placebo group. gress in 2018 urged the FDA to convene a In a confirmatory phase 3 trial, a RedHill task force to examine the issue and offer po- statement noted that H pylori was eradi- tential solutions. In response, officials from cated in 84% of patients in the Talicia the FDA and several other federal agencies group compared with 58% in a group that analyzed 163 drugs that were in short sup- received amoxicillin and omeprazole. ply from 2013 to 2017 and compared them Treatment with 2 CFTR modulators is ef- Adverse reactions included nausea, vomit- with more readily available drugs. ing, and nasal congestion. fectiveforpeoplewithcysticfibrosiswhoare “Shortage drugs were more likely to be “The clinical studies for Talicia demon- homozygous for that mutation. But those relatively low-price and financially unattract- strated high efficacy in eradication of who have a single F508del allele and an- ive drugs,” former Acting Commissioner Ned H pylori,” lead investigator David Y. Graham, other CFTR mutation—about 2000 are Sharpless, MD, and Janet Woodcock, MD, di- MD, of the Baylor College of Medicine in known—have no options to treat the under- rector of the FDA’s Center for Drug Evalua- Houston, said in a statement. The studies lying disease. These mutations are called tion and Research, wrote in a statement. “found zero resistance to rifabutin and minimal function because they result in Sharpless and Woodcock indicated that showed 17% resistance to clarithromycin, a either no CFTR protein production or non- prices rarely increased after shortages be- current standard-of-care macrolide antibi- response to CFTR modulators. gan and production subsequently didn’t rise otic, consistent with current data showing Efficacy was demonstrated in 2 phase 3 to meet demand. Many manufacturers, they trials involving patients with cystic fibrosis. that clarithromycin-containing therapies noted, discontinued drugs that no longer fail in approximately 25%-40% of cases,” In 1 trial, 403 patients with F508del mini- were profitable. mal function genotypes were randomized he added. “These results suggest a broken market- A2017 meta-analysis reported that to receive the triple-drug combination place,” they wrote. or placebo. After 24 weeks, the treated 4.4 billion people—more than half the Although solutions aren’t easy,Sharpless world’s population—had H pylori infection patients had improvements in lung func- and Woodcock recommended that data be tion, pulmonary exacerbations, sweat chlo- in 2015. Prevalence in the US general popu- gathered to quantify the effects of short- lation was 35.6%, but more than doubled ride concentration, and respiratory-related ages, a rating system be developed to quality of life. to 74.8% among Alaska Natives. Nigeria’s inform purchasers and consumers about 87.7% prevalence was the world’s highest; In the other trial, 107 patients who were manufacturers’ quality management, and 18.9% in Switzerland was the lowest. homozygous for the F508del mutation were contracting methods be updated to pro- randomized to receive Trikafta or 2 of its vide manufacturers, especially producers components, tezacaftor and ivacaftor. Af- of older generic drugs, with sustainable Patients With Cystic Fibrosis Have New Triple-Drug Combination ter 4 weeks, the investigators said that pa- returns. − Rebecca Voelker, MSJ Thirty years after investigators discovered tients treated with the 3-drug combination Note: Source references are available through the genetic defect that causes cystic fibro- embedded hyperlinks in the article text online. had “clinically robust” benefits in lung func- 2068 JAMA December 3, 2019 Volume 322, Number 21 (Reprinted) jama.com © 2019 American Medical Association. All rights reserved. James Cavallini/sciencesource.com

Journal

JAMAAmerican Medical Association

Published: Dec 3, 2019

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off